90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies

Giovanni Paganelli, L. Bodei, D. Handkiewicz Junak, P. Rocca, S. Papi, M. Lopera Sierra, M. Gatti, M. Chinol, M. Bartolomei, M. Fiorenza, C. Grana

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Somatostatin receptors type 2 (sst2) are expressed in high concentration on numerous neudoendocrine tumors. The successful use of radiolabeled somatostatin analogs in imaging promoted further studies in utilizing them in radiopeptide therapy. The somatostatin analog 90Y-DOTA-D-Phe1-Try3]octreotide (DOTATOC) (DOTA: 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid) possesses favorable characteristic for its therapeutic use; shows high affinity for sst2, moderately high affinity for sst5, and intermediate affinity for sst3; high hydrophilicity; stable and facile labeling with 111 In and 90 Y. In this article we report our experience with 90Y-DOTATOC in neuroendocrine tumors. Eighty-seven patients with neuroendocrine tumors were treated with a cumulated activity ranging from 7.4 to 20.2 GBq. Most patients responded with stabilization of disease (48%); however, objective responses were observed in 28% of patients (5% complete response). No major acute reactions were observed up to the activity of 5.55 GBq per cycle. The dose limiting was bone marrow toxicity and the maximal tolerated dose was defined as 5.18 GBq.

Original languageEnglish
Pages (from-to)393-398
Number of pages6
JournalBiopolymers
Volume66
Issue number6
DOIs
Publication statusPublished - 2002

Fingerprint

Octreotide
Tumors
Neuroendocrine Tumors
Somatostatin
Neoplasms
Maximum Tolerated Dose
Hydrophilicity
Therapeutic Uses
Hydrophobic and Hydrophilic Interactions
Labeling
Toxicity
Bone
Therapeutics
Stabilization
Bone Marrow
Imaging techniques
Acids
somatostatin receptor 2

Keywords

  • Y-DOTA-D-Phe-Try-Octreotide (Y-DOTATOC)
  • Neuroendocrine tumors
  • Radiopeptide therapy
  • Somatostatin analogs

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Biophysics

Cite this

Paganelli, G., Bodei, L., Handkiewicz Junak, D., Rocca, P., Papi, S., Lopera Sierra, M., ... Grana, C. (2002). 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers, 66(6), 393-398. https://doi.org/10.1002/bip.10349

90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. / Paganelli, Giovanni; Bodei, L.; Handkiewicz Junak, D.; Rocca, P.; Papi, S.; Lopera Sierra, M.; Gatti, M.; Chinol, M.; Bartolomei, M.; Fiorenza, M.; Grana, C.

In: Biopolymers, Vol. 66, No. 6, 2002, p. 393-398.

Research output: Contribution to journalArticle

Paganelli, G, Bodei, L, Handkiewicz Junak, D, Rocca, P, Papi, S, Lopera Sierra, M, Gatti, M, Chinol, M, Bartolomei, M, Fiorenza, M & Grana, C 2002, ' 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies', Biopolymers, vol. 66, no. 6, pp. 393-398. https://doi.org/10.1002/bip.10349
Paganelli G, Bodei L, Handkiewicz Junak D, Rocca P, Papi S, Lopera Sierra M et al. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers. 2002;66(6):393-398. https://doi.org/10.1002/bip.10349
Paganelli, Giovanni ; Bodei, L. ; Handkiewicz Junak, D. ; Rocca, P. ; Papi, S. ; Lopera Sierra, M. ; Gatti, M. ; Chinol, M. ; Bartolomei, M. ; Fiorenza, M. ; Grana, C. / 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. In: Biopolymers. 2002 ; Vol. 66, No. 6. pp. 393-398.
@article{74c336a304c04ec3bbe9c2fd55e64ec2,
title = "90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies",
abstract = "Somatostatin receptors type 2 (sst2) are expressed in high concentration on numerous neudoendocrine tumors. The successful use of radiolabeled somatostatin analogs in imaging promoted further studies in utilizing them in radiopeptide therapy. The somatostatin analog 90Y-DOTA-D-Phe1-Try3]octreotide (DOTATOC) (DOTA: 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid) possesses favorable characteristic for its therapeutic use; shows high affinity for sst2, moderately high affinity for sst5, and intermediate affinity for sst3; high hydrophilicity; stable and facile labeling with 111 In and 90 Y. In this article we report our experience with 90Y-DOTATOC in neuroendocrine tumors. Eighty-seven patients with neuroendocrine tumors were treated with a cumulated activity ranging from 7.4 to 20.2 GBq. Most patients responded with stabilization of disease (48{\%}); however, objective responses were observed in 28{\%} of patients (5{\%} complete response). No major acute reactions were observed up to the activity of 5.55 GBq per cycle. The dose limiting was bone marrow toxicity and the maximal tolerated dose was defined as 5.18 GBq.",
keywords = "Y-DOTA-D-Phe-Try-Octreotide (Y-DOTATOC), Neuroendocrine tumors, Radiopeptide therapy, Somatostatin analogs",
author = "Giovanni Paganelli and L. Bodei and {Handkiewicz Junak}, D. and P. Rocca and S. Papi and {Lopera Sierra}, M. and M. Gatti and M. Chinol and M. Bartolomei and M. Fiorenza and C. Grana",
year = "2002",
doi = "10.1002/bip.10349",
language = "English",
volume = "66",
pages = "393--398",
journal = "Biopolymers",
issn = "0006-3525",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies

AU - Paganelli, Giovanni

AU - Bodei, L.

AU - Handkiewicz Junak, D.

AU - Rocca, P.

AU - Papi, S.

AU - Lopera Sierra, M.

AU - Gatti, M.

AU - Chinol, M.

AU - Bartolomei, M.

AU - Fiorenza, M.

AU - Grana, C.

PY - 2002

Y1 - 2002

N2 - Somatostatin receptors type 2 (sst2) are expressed in high concentration on numerous neudoendocrine tumors. The successful use of radiolabeled somatostatin analogs in imaging promoted further studies in utilizing them in radiopeptide therapy. The somatostatin analog 90Y-DOTA-D-Phe1-Try3]octreotide (DOTATOC) (DOTA: 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid) possesses favorable characteristic for its therapeutic use; shows high affinity for sst2, moderately high affinity for sst5, and intermediate affinity for sst3; high hydrophilicity; stable and facile labeling with 111 In and 90 Y. In this article we report our experience with 90Y-DOTATOC in neuroendocrine tumors. Eighty-seven patients with neuroendocrine tumors were treated with a cumulated activity ranging from 7.4 to 20.2 GBq. Most patients responded with stabilization of disease (48%); however, objective responses were observed in 28% of patients (5% complete response). No major acute reactions were observed up to the activity of 5.55 GBq per cycle. The dose limiting was bone marrow toxicity and the maximal tolerated dose was defined as 5.18 GBq.

AB - Somatostatin receptors type 2 (sst2) are expressed in high concentration on numerous neudoendocrine tumors. The successful use of radiolabeled somatostatin analogs in imaging promoted further studies in utilizing them in radiopeptide therapy. The somatostatin analog 90Y-DOTA-D-Phe1-Try3]octreotide (DOTATOC) (DOTA: 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid) possesses favorable characteristic for its therapeutic use; shows high affinity for sst2, moderately high affinity for sst5, and intermediate affinity for sst3; high hydrophilicity; stable and facile labeling with 111 In and 90 Y. In this article we report our experience with 90Y-DOTATOC in neuroendocrine tumors. Eighty-seven patients with neuroendocrine tumors were treated with a cumulated activity ranging from 7.4 to 20.2 GBq. Most patients responded with stabilization of disease (48%); however, objective responses were observed in 28% of patients (5% complete response). No major acute reactions were observed up to the activity of 5.55 GBq per cycle. The dose limiting was bone marrow toxicity and the maximal tolerated dose was defined as 5.18 GBq.

KW - Y-DOTA-D-Phe-Try-Octreotide (Y-DOTATOC)

KW - Neuroendocrine tumors

KW - Radiopeptide therapy

KW - Somatostatin analogs

UR - http://www.scopus.com/inward/record.url?scp=0036976703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036976703&partnerID=8YFLogxK

U2 - 10.1002/bip.10349

DO - 10.1002/bip.10349

M3 - Article

C2 - 12658726

AN - SCOPUS:0036976703

VL - 66

SP - 393

EP - 398

JO - Biopolymers

JF - Biopolymers

SN - 0006-3525

IS - 6

ER -